
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Certara announced that the Brazilian National Health Surveillance Agency, ANVISA is now also employing Certara’s Phoenix WinNonlin software for reviewing drug regulatory submissions. With the adoption of Certara's software, reviewed studies will be evauated to see if they follow good bioequivalence practices.
Read the full release






